Jon Napitupulu

Vittoria Biotherapeutics is presenting its Phase 1 clinical trial results for VIPER-101, a gene-edited CAR-T therapy targeting CD5-positive T-cell...

SCYNEXIS has restarted patient dosing in its Phase 3 MARIO study of oral ibrexafungerp for invasive candidiasis after resolving...

Candel Therapeutics announced that its lead immunotherapy candidate, CAN-2409, received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA...

Halberd Corporation, in collaboration with Athena Telemedicine Partners, reports positive clinical results for its patent-pending LDX compound in treating...

Syncromune’s Phase 1 clinical trial of SYNC-T Therapy SV-102 in patients with metastatic castration-resistant prostate cancer (mCRPC) showed an...

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended conditional marketing authorization for mirdametinib, a...

BriaCell Therapeutics Corp. announced positive Phase 2 clinical trial data for its Bria-IMT™ immunotherapy in metastatic breast cancer, demonstrating...

Iovance Biotherapeutics announced five-year follow-up data from the Phase 2 C-144-01 trial of its tumor-infiltrating lymphocyte (TIL) therapy, Amtagvi...

Merus N.V. announced interim phase 2 trial data for petosemtamab combined with pembrolizumab in treating head and neck squamous...

ImCheck Therapeutics announced positive interim results from its Phase I/II EVICTION study of ICT01, a novel γ9δ2 T-cell activator,...